If you have been reading about Synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-14. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Ricky Dyson (born 28 September 1985) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Originally from the Epping Football Club, and drafted at number 44 in the 2003 National Draft, Dyson played mainly as a midfielder.
==== Suggestibility ==== While research from the 1960s indicated increased suggestibility under the influence of LSD among both mentally ill and healthy individuals, the CIA and US Department of Defense conducted secret mind control experiments in which LSD was administered to unwitting human subjects as part of secret operations MKUltra and Operation Midnight Climax.
In February 2025, following the death of long time mayor Republican Benedict Romeo, the position of the mayor of the Borough of Cresskill was filled by John Morgan. Morgan who previously held the position of President the Board of Health, served on an interim basis until the November 2025, and then was elected in the November 2025 elections. Long time mayor Benedict Romeo served six terms as mayor, having first been elected to the position in 1999 died at the age of 77.
Sources: en.wikipedia.org
Succimer aci or dimercaptosuccinic acid is the organosulfur compound with the formula (HSCH)2(CO2H)2. It is a dicarboxylic acid containing a two thiol functional groups. It is a white solid. Like many dithiols, it is a chelating agent, forming metal thiolate complexes.
At the moment that each or every one of them is caught, whatever the circumstances, this resolution will be executed, without giving rise to minutes that provide requests and relationships capable of compromising compliance with this order and the honor of Your Excellency. This punishment must be the basis of the stability of the new system and a lesson for the chiefs of Peru, who advance to a thousand excesses for the hope of impunity and is at the same time the proof of the usefulness and energy with which this Expedition fills the important objects what is it intended for." There were also signs of Peruvian-phobia on the part of the Argentines of the Junta when Manuel Belgrano exposed on July 6, 1816, in front of the deputies of the Congress of Tucumán in two meetings, a proposal to establish an almost nominal monarchy, discussing first about choosing a European prince and then a Peruvian sovereign from the descendants of the Incas to offer the throne, it was most likely projected that the title would correspond to Juan Bautista Túpac Amaru, the only known surviving brother of the Inca noble, Túpac Amaru II, although they also considered Dionisio Inca Yupanqui, a mestizo jurist and soldier who had been educated in Europe and who was the representative of Peru at the Cortes of Cádiz, or Juan Andrés Jiménez de León Manco Cápac, a mestizo cleric and soldier who earned his fame for opposing the excessive collection of tribute and that he participated as a military commander in the uprising of Juan José Castelli.
== History == The Human Genetics Society of Australasia was founded subsequent to the growth in the field of genetics that occurred during the mid-twentieth century. During this time, the role that genetics plays in human health and disease became increasingly recognized. Genetic diagnostic techniques (in particular, in cytogenetics) were progressing rapidly. This coincided with the appreciation by medical specialists that genetic disorders, especially inborn errors of metabolism and birth defects, were of clinical interest. In 1976, a meeting in clinical genetics was held as part of the celebrations of the Centenary Year of the Adelaide Children's Hospital. The meeting involved several high-profile international speakers, most of the senior medical practitioners with an interest in heritable disease working in Australia and New Zealand, and delegates of the annual meeting of local cytogeneticists. The group agreed that a small working group should be charged with setting up a human genetics society for the region. Subsequently, the Human Genetics Society of Australasia was formally incorporated in South Australia in 1977 to serve the Australia and New Zealand region. The original group consisted of 19 Foundation Members, paying just $A10 per annum for membership.
== Monomer preparation == To prepare and oligopeptide with both a terminal azide and terminal alkyne two modifications must be carried out. The first is the amidation of the oligopeptide's C-terminus by propargylamine. This would done with all other reaction groups protected and with the C-terminus activated.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.